Company Overview of VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc.
Key Executives for VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc.
|Jeff R. Baxter FCMA||26 Relationships||Chief Executive Officer, President and Director||56|
|Francisco Diaz-Mitoma M.D., Ph.D.||10 Relationships||Founder||62|
VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|Steven S. Gillis M.D., Ph.D.||163 Relationships||Arch Venture Partners, L.P.||64|
|Jeff R. Baxter FCMA||26 Relationships||VBI Vaccines Inc.||56|
|Scott Requadt J.D., MBA||21 Relationships||Phoenix Strategy Investments, LLC||49|
|Alan P. Timmins||17 Relationships||Yamhill Valley Vineyards Inc||57|
|Stanley A. Plotkin M.D.||80 Relationships||Mymetics Corporation||84|
VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee||Alan P. Timmins||17 Relationships||3 Executives|
|Compensation Committee J.D., MBA||Scott Requadt||21 Relationships||2 Executives|
|Nominating Committee M.D., Ph.D.||Steven S. Gillis||163 Relationships||3 Executives|
|Corporate Governance Committee M.D., Ph.D.||Steven S. Gillis||163 Relationships||3 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$580.0K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.